AU766514B2 - Protein formulations - Google Patents

Protein formulations Download PDF

Info

Publication number
AU766514B2
AU766514B2 AU35916/99A AU3591699A AU766514B2 AU 766514 B2 AU766514 B2 AU 766514B2 AU 35916/99 A AU35916/99 A AU 35916/99A AU 3591699 A AU3591699 A AU 3591699A AU 766514 B2 AU766514 B2 AU 766514B2
Authority
AU
Australia
Prior art keywords
parathyroid hormone
pharmaceutical formulation
pth
human
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU35916/99A
Other languages
English (en)
Other versions
AU3591699A (en
Inventor
Martin Billger
Mikael Brulls
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire NPS Pharmaceuticals Inc
Original Assignee
NPS Allelix Corp Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NPS Allelix Corp Canada filed Critical NPS Allelix Corp Canada
Publication of AU3591699A publication Critical patent/AU3591699A/en
Assigned to NPS ALLELIX CORP. reassignment NPS ALLELIX CORP. Amend patent request/document other than specification (104) Assignors: ALLELIX BIOPHARMACEUTICALS INC.
Application granted granted Critical
Publication of AU766514B2 publication Critical patent/AU766514B2/en
Priority to AU2004200156A priority Critical patent/AU2004200156B2/en
Assigned to NPS PHARMACEUTICALS, INC. reassignment NPS PHARMACEUTICALS, INC. Alteration of Name(s) in Register under S187 Assignors: NPS ALLELIX CORP.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU35916/99A 1998-04-28 1999-04-26 Protein formulations Expired AU766514B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2004200156A AU2004200156B2 (en) 1998-04-28 2004-01-16 Protein formulations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9801495A SE9801495D0 (sv) 1998-04-28 1998-04-28 Protein formulationa
SE9801495 1998-04-28
PCT/CA1999/000376 WO1999055353A2 (en) 1998-04-28 1999-04-26 Protein formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2004200156A Division AU2004200156B2 (en) 1998-04-28 2004-01-16 Protein formulations

Publications (2)

Publication Number Publication Date
AU3591699A AU3591699A (en) 1999-11-16
AU766514B2 true AU766514B2 (en) 2003-10-16

Family

ID=20411122

Family Applications (2)

Application Number Title Priority Date Filing Date
AU35916/99A Expired AU766514B2 (en) 1998-04-28 1999-04-26 Protein formulations
AU2004200156A Expired AU2004200156B2 (en) 1998-04-28 2004-01-16 Protein formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2004200156A Expired AU2004200156B2 (en) 1998-04-28 2004-01-16 Protein formulations

Country Status (24)

Country Link
US (1) US20050209144A1 (enExample)
EP (1) EP1079803B1 (enExample)
JP (2) JP4733267B2 (enExample)
KR (1) KR100579872B1 (enExample)
CN (1) CN1172658C (enExample)
AT (1) ATE273693T1 (enExample)
AU (2) AU766514B2 (enExample)
BR (1) BR9909958A (enExample)
CA (1) CA2329800C (enExample)
CY (1) CY2006006I2 (enExample)
DE (3) DE69919533T2 (enExample)
DK (1) DK1079803T3 (enExample)
ES (1) ES2224637T3 (enExample)
FR (1) FR06C0032I2 (enExample)
HK (1) HK1041218B (enExample)
IL (1) IL139320A (enExample)
LU (1) LU91281I2 (enExample)
NL (1) NL300243I2 (enExample)
NZ (1) NZ508269A (enExample)
PT (1) PT1079803E (enExample)
SE (1) SE9801495D0 (enExample)
SI (1) SI1079803T1 (enExample)
WO (1) WO1999055353A2 (enExample)
ZA (1) ZA200006040B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa
WO2005014034A1 (en) * 2003-07-14 2005-02-17 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
WO2007059470A2 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
DK2073789T3 (da) 2006-10-03 2019-08-05 Radius Health Inc Stabil sammensætning omfattende et knogle-anabolisk protein, nemlig en pthrp-analog, og anvendelser deraf
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
FR2925333B1 (fr) * 2007-12-19 2012-04-13 Farid Bennis Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
JP2009091363A (ja) * 2008-11-21 2009-04-30 Asahi Kasei Pharma Kk Ｐｔｈの安定化水溶液注射剤
WO2011071480A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
CN108195965B (zh) * 2011-06-07 2021-02-23 旭化成制药株式会社 含pth肽冷冻干燥制剂的检査方法及包含该含pth肽冷冻干燥制剂的医药品的制造方法
CN103301058A (zh) * 2013-06-17 2013-09-18 深圳翰宇药业股份有限公司 一种特立帕肽注射用组合物及其制备方法和制剂
ES2939940T3 (es) 2014-03-28 2023-04-28 Univ Duke Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
MX384605B (es) 2015-04-29 2025-03-14 Radius Pharmaceuticals Inc Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.
CN106309358A (zh) * 2015-06-29 2017-01-11 成都金凯生物技术有限公司 含有人甲状旁腺激素的药物组合物及其制备方法与用途
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
CN108333360A (zh) * 2017-01-19 2018-07-27 深圳市新产业生物医学工程股份有限公司 胃泌素释放肽前体稀释液及其应用和试剂盒
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
US20200289621A1 (en) * 2017-09-22 2020-09-17 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
CN108159404B (zh) * 2018-01-05 2019-08-27 北京博康健基因科技有限公司 重组人甲状旁腺激素制剂及其制备方法
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
US12441745B2 (en) 2019-02-12 2025-10-14 Radius Pharmaceuticals, Inc. Processes and compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014429A1 (de) * 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische darreichungsformen enthaltend parathormon

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5744444A (en) * 1989-10-27 1998-04-28 Haemopep Pharma Gmbh HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5547939A (en) * 1991-06-14 1996-08-20 The Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
JP2662842B2 (ja) * 1991-12-09 1997-10-15 旭化成工業株式会社 パラサイロイドホルモンの安定化組成物
ES2129048T3 (es) * 1991-12-09 1999-06-01 Asahi Chemical Ind Composicion estabilizada de hormona paratiroide.
DK0679088T3 (da) * 1992-09-29 2002-10-28 Inhale Therapeutic Syst Pulmonal levering af aktive fragmenter af parathyreoideaea hormon
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
JPH09157294A (ja) * 1995-06-15 1997-06-17 Takeda Chem Ind Ltd 副甲状腺ホルモン誘導体
JP4053107B2 (ja) * 1996-02-01 2008-02-27 中外製薬株式会社 血小板減少症の予防剤および治療剤
US5964807A (en) * 1996-08-08 1999-10-12 Trustees Of The University Of Pennsylvania Compositions and methods for intervertebral disc reformation
DE19733651A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014429A1 (de) * 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische darreichungsformen enthaltend parathormon

Also Published As

Publication number Publication date
DE122006000057I2 (de) 2009-11-05
DE122006000057I1 (de) 2007-01-04
KR100579872B1 (ko) 2006-05-12
DK1079803T3 (da) 2004-11-22
CY2006006I1 (el) 2009-11-04
HK1041218A1 (en) 2002-07-05
WO1999055353A3 (en) 2000-01-13
JP2011105739A (ja) 2011-06-02
AU2004200156A1 (en) 2004-02-12
HK1041218B (zh) 2005-03-18
ZA200006040B (en) 2002-01-28
WO1999055353A2 (en) 1999-11-04
EP1079803B1 (en) 2004-08-18
NL300243I1 (nl) 2006-12-01
KR20010052276A (ko) 2001-06-25
JP5753692B2 (ja) 2015-07-22
JP2002512973A (ja) 2002-05-08
LU91281I2 (fr) 2006-12-19
AU3591699A (en) 1999-11-16
NZ508269A (en) 2003-12-19
CY2006006I2 (el) 2009-11-04
IL139320A0 (en) 2001-11-25
BR9909958A (pt) 2000-12-26
AU2004200156B2 (en) 2005-12-15
EP1079803A2 (en) 2001-03-07
FR06C0032I1 (enExample) 2006-11-24
JP4733267B2 (ja) 2011-07-27
NL300243I2 (nl) 2007-02-01
IL139320A (en) 2007-06-17
ATE273693T1 (de) 2004-09-15
CA2329800A1 (en) 1999-11-04
FR06C0032I2 (fr) 2007-04-27
DE69919533D1 (de) 2004-09-23
SI1079803T1 (en) 2005-02-28
DE69919533T2 (de) 2005-09-08
CN1319003A (zh) 2001-10-24
CN1172658C (zh) 2004-10-27
CA2329800C (en) 2004-06-15
ES2224637T3 (es) 2005-03-01
PT1079803E (pt) 2004-11-30
SE9801495D0 (sv) 1998-04-28
US20050209144A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
EP1079803B1 (en) Protein formulations
JP4405666B2 (ja) 安定化テリパラチド溶液剤
EP2219665B1 (en) Parathyroid hormone formulations and uses thereof
US5661125A (en) Stable and preserved erythropoietin compositions
JP4353544B2 (ja) アミリン作動薬ペプチド用製剤
RU2529952C2 (ru) Новые производные инсулина с сильно замедленным профилем время/действие
US20010043934A1 (en) Formulations for amylin agonist peptides
CN101537173A (zh) 长期稳定的制剂
WO1999031137A1 (en) Crystalline teriparatide
GB1560933A (en) Biologically activy polypeptides
AU2006201087A1 (en) Protein formulations
JP4865728B2 (ja) ポリペプチドの三硫化物誘導体の形成を防止する方法
MXPA00010640A (en) Protein formulations
EP0063328A2 (en) Compositions containing secretin and method for preventing the adsorption of secretin
HK1146465B (en) Parathyroid hormone formulations and uses thereof
HK1130198A (en) Parathyroid hormone formulations and uses thereof
MXPA00005655A (en) Stabilized teriparatide solutions
JP2009149684A (ja) アミリン作動薬ペプチド用製剤

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: NPS ALLELIX CORP.

Free format text: FORMER NAME: ALLELIX BIOPHARMACEUTICALS INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired